Custom RNA vaccine shows promise in fighting tough breast cancer
NCT ID NCT02316457
First seen Mar 21, 2026 · Last updated May 16, 2026 · Updated 10 times
Summary
This early-stage study tested a personalized RNA vaccine designed to train the immune system to attack triple negative breast cancer cells. 42 patients received custom-made vaccines based on their tumor's unique genetic makeup. The main goal was to check safety and see if the vaccine could trigger an immune response against the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER (TRIPLE NEGATIVE BREAST CANCER (TNBC)) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dr. Horst Schmidt-Kliniken Wiesbaden
Wiesbaden, 65199, Germany
-
Johannes Gutenberg University
Mainz, RLP, 55131, Germany
-
National Center for Tumor Diseases (NCT)
Heidelberg, 69120, Germany
-
Uppsala University Hospital
Uppsala, 75185, Sweden
Conditions
Explore the condition pages connected to this study.